Table 2.

HIV transmission clusters between 2015 and 2021 involving Netherlands Cohort Study on Acute HIV infection participants and their baseline characteristics.

Sex	Subtype	HIV diagnosis	Region enrolled	Fiebig at diagnosis	CD4+ count at diagnosis	Plasma HIV-RNA at diagnosis	Mutations at baseline	Drug class
Male	B	09/2017	Rotterdam	F6	700	22 600	T215S	NRTI
Male	B	07/2019	Rotterdam	F5	300	19 400 000	T215S	NRTI
Male	B	08/2019	Rotterdam	F2	270	33 100 000	T215S	NRTI
Male	B	11/2019	Amsterdam	Unknown	808	2 263 455	T215S	NRTI
Male	B	10/2015	Amsterdam	F4	530	84 675	None	None
Male	B	12/2015	Amsterdam	F6	590	33 862	None	None
Male	B	10/2018	Amsterdam	F2	580	8 356 721	None	None
Male	B	04/2019	Amsterdam	F3	340	10 000 000	None	None
Male	B	10/2018	Rotterdam	F4	200	10 000 000	None	None
Male	B	12/2018	Rotterdam	F5	1200	46 700	None	None
Male	B	06/2018	Amsterdam	F5	750	4379	None	None
Male	B	03/2018	Amsterdam	F5	530	69 028	None	None
Male	B	03/2016	Amsterdam	F5	250	1 420 000	None	None
Male	B	08/2016	Amsterdam	F1	510	98 700	None	None
Male	B	03/2019	Amsterdam	F6	270	1 195 913	None	None
Male	B	08/2017	Leiden	F5	269	41 400	None	None
Male	B	08/2017	Leiden	F5	438	16 000	None	None
Male	B	01/2018	Leiden	F6	680	88 400	None	None
Male	B	10/2016	Amsterdam	F5	470	650 000	None	None
Male	B	04/2017	Amsterdam	F6	705	775 502	None	None
Male	CRF02_AG	05/2017	Rotterdam	F5	270	1 060 000	None	None
Male	CRF02_AG	09/2017	Rotterdam	F5	420	376 000	None	None
Male	CRF02_AG	08/2017	Rotterdam	F6	570	43 300	None	None

Participants diagnosed in Fiebig VI could only be included in case of a negative test result available in the previous 6 months; CD4⁺ T-cell counts are presented in cells/μl; HIV-RNA is presented in RNA copies/ml. NRTI, nucleoside reverse transcriptase inhibitors.